Overview

Hydrafinil (9-fluorenol, also marketed as fluorenol) is a eugeroic (wakefulness-promoting) compound structurally related to the fluorene family. It was first identified in research by Cephalon Inc. (the original developers of modafinil) as part of a series exploring wakefulness-promoting agents beyond the modafinil/adrafinil scaffold. Hydrafinil acts primarily as a weak but selective dopamine reuptake inhibitor (DRI), with significantly less activity at the norepinephrine transporter compared to modafinil. Preclinical studies demonstrated that hydrafinil produces wakefulness in sleep-deprived animal models at doses roughly 39% more potent than modafinil on a per-weight basis, while exhibiting a more selective pharmacological profile.

Unlike modafinil and adrafinil (its prodrug predecessor), hydrafinil does not appear to significantly affect histamine, orexin, or GABA systems at standard doses, resulting in a cleaner stimulant profile with reportedly less anxiety and jitteriness. Users in the nootropic community describe it as providing smoother, less intense wakefulness compared to modafinil, with a shorter duration of action (approximately 6–8 hours versus 12–15 hours for modafinil). This shorter duration can be advantageous for afternoon dosing without sleep disruption. Typical reported doses range from 50–150 mg, taken orally, though no human clinical trials have established formal dosing guidelines.

It is important to note that hydrafinil remains a research chemical with no regulatory approval for human use in any jurisdiction. The limited human safety data means that long-term risks are unknown, and potential hepatotoxicity (a concern with related fluorenol compounds) has not been adequately studied. Users exploring eugeroic compounds may also consider adrafinil (which has a longer track record) or discuss prescription modafinil with a physician. Hydrafinil is sometimes included in nootropic stacks alongside caffeine and l-theanine for balanced alertness, though such combinations are based on anecdotal reports rather than clinical evidence.

Mechanism of Action

Hydrafinil (9-fluorenol) is a substituted fluorenol derivative classified as a eugeroic, or wakefulness-promoting agent. While its complete mechanism of action remains under investigation, the primary pathway involves weak dopamine reuptake inhibition. By blocking the dopamine transporter (DAT), hydrafinil increases the extracellular concentration of dopamine in the synaptic cleft, which is thought to be the main contributor to its wakefulness-promoting and cognitive-enhancing effects.

Beyond dopaminergic activity, hydrafinil may also modulate the histaminergic system. Research suggests it can increase histamine levels in the hypothalamus, a brain region that serves as a key regulator of the sleep-wake cycle. Histamine is one of the primary wake-promoting neurotransmitters, and enhanced histaminergic signaling would reinforce the arousal effects of dopamine modulation.

Some evidence also suggests activity at serotonin receptors, though this aspect of the mechanism is less well-characterized. Compared to modafinil, hydrafinil has been reported to have stronger wakefulness-promoting effects with less interference in normal sleep architecture, though clinical data remains limited.

Reconstitution Calculator

Research

Safety Profile

Safety Profile: Hydrafinil (9-Fluorenol)

Common Side Effects

• Headache (most commonly reported, consistent with eugeroic/wakefulness-promoting class effects)
• Insomnia and disrupted sleep architecture, especially with afternoon or evening dosing
• Anxiety, nervousness, and restlessness
• Nausea and mild gastrointestinal discomfort
• Dry mouth
• Reduced appetite
• Increased heart rate and mild blood pressure elevation
• Irritability and mood fluctuations

Serious Adverse Effects

• Hepatotoxicity: 9-Fluorenol has shown hepatotoxic potential in preclinical studies; liver enzyme elevations reported anecdotally by users
• Cardiovascular stress: Stimulant-like effects may cause tachycardia, hypertension, and palpitations; long-term cardiovascular safety unknown
• Psychiatric effects: Anxiety exacerbation, agitation, and potential for psychotic symptoms at high doses; may trigger mania in predisposed individuals
• Dependence and withdrawal: While marketed as having low abuse potential, chronic use of wakefulness-promoting agents can lead to psychological dependence; withdrawal fatigue and hypersomnia reported
• No human clinical trials: Hydrafinil has never undergone formal human safety or efficacy studies; all safety information is extrapolated from preclinical data and anecdotal reports

Contraindications

• Known liver disease or elevated baseline liver enzymes
• Anxiety disorders, panic disorder, or psychotic disorders
• Cardiovascular disease (uncontrolled hypertension, arrhythmias, coronary artery disease)
• Pregnancy and lactation (no safety data whatsoever)
• Concurrent use of other stimulants or wakefulness-promoting agents
• History of substance abuse (unknown addiction potential)
• Children and adolescents
• Known hypersensitivity to fluorenol compounds

Drug Interactions

• Other stimulants (modafinil, amphetamines, caffeine): Additive cardiovascular stimulation and CNS excitation; increased risk of anxiety, tachycardia, and hypertension
• MAO inhibitors: Potential for hypertensive crisis with concurrent stimulant use
• CYP450 substrates: Metabolic profile poorly characterized; assume potential for enzyme induction or inhibition
• Hepatotoxic drugs: Additive liver injury risk; avoid concurrent use with acetaminophen (high dose), statins, or other hepatotoxic agents
• Anxiolytics and sedatives: Pharmacological antagonism; may reduce effectiveness of anxiolytic or sleep medications
• Antihypertensives: Stimulant effects may counteract blood pressure-lowering medications

Population-Specific Considerations

• Pregnancy/Lactation: Absolutely contraindicated; no reproductive safety data exists
• Children/Adolescents: Not under any circumstances; developing CNS is highly vulnerable to uncharacterized compounds
• Elderly: Avoid; higher susceptibility to cardiovascular and hepatic adverse effects; no geriatric safety data
• Liver disease: Contraindicated due to hepatotoxicity signal
• Psychiatric patients: Avoid in anxiety, bipolar, and psychotic disorders
• Note: Hydrafinil is an unregulated research chemical not approved for human consumption by any regulatory agency. It is sold as a research compound only. Users assume all risk, and the complete absence of clinical safety data makes informed risk assessment impossible

Pharmacokinetic Profile